Trial Profile
A Pivotal Phase II 90-day study of BTI-410 in Type 1 diabetes patients on immunosuppression therapy after kidney transplant surgery.
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 12 Jun 2023
Price :
$35
*
At a glance
- Drugs Human proislet peptide (Primary)
- Indications Type 1 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors Boston Therapeutics; Nanomix Corporation
- 11 Apr 2018 New trial record
- 27 Mar 2018 According to a Boston Therapeutics media release, this trial is planned to initiate during the first half of 2018.